



• **Name:** Minlee Kim

• **Current Position:** CTO at Genolution Inc.

• **Country:** Korea

• **Educational Background:**

2009 – 2015 Yale University, New Haven, CT, USA
Ph.D., Dept. of Molecular, Cellular and Developmental Biology

2005 – 2009 Brandeis University, Waltham, MA, USA
B.S., Biology, Highest honors in Biology, Cum Laude

• **Professional Experience:**

03/2018 – Present Genolution Inc. Seoul, Korea
CTO

01/2016 – 01/2018 Samsung Bioepis, Incheon, Korea
Senior Scientist

06/2015 – 12/2015 Beth Israel Deaconess Medical Center, Boston, MA, USA
Post-doctoral Research Assistant, Dept. of Genetics

06-08/2010 Bristol-Myers Squibb, Wallingford, CT, USA
Intern, Lead Discovery Department

• **Main Scientific Publications:**

Kim, M. Kogan, N. Slack FJ. Cis-acting elements in its 3' UTR mediate post-transcriptional regulation of KRAS. *Oncotarget*. 2016;7(11):11770-84. PMID: 26930719

Kim, M, Slack, FJ. MicroRNA-mediated regulation of KRAS in cancer. *J Hematol Oncol*. 2014;7(1):84. PMID: 25433809

Kim, M, Chen X, Chin LJ, et al. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. *Cell Cycle*. 2014;13(6):1030-1040. PMID: 24552817

Kim, M, Kasinski, AL, Slack, FJ. MicroRNA therapeutics in preclinical cancer models. *Lancet Oncol*. 2011;12(4):319-321. PMID: 21463831

Hicks, WM, Kim, M, Haber, JE. Increased mutagenesis and unique mutation signature associated with mitotic gene conversion. *Science*. 2010;329(5987):82-85. PMID: 20595613